Goldman Sachs’s Akero Therapeutics AKRO Stock Holding History

Goldman Sachs’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-27,900	Closed	-$1.49M	–	6308
2025 Q2	$1.49M	Buy	+27,900	New	+$1.27M	﹤0.01%	4406
2024 Q4	–	Sell	-31,500	Closed	-$904K	–	6002
2024 Q3	$904K	Buy	+31,500	New	+$821K	﹤0.01%	4704

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Goldman Sachs's AKRO Position: Q4 2025 in Review

Goldman Sachs sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 855,766 shares — an estimated $40.6M sold.

Goldman Sachs first reported a position in AKRO in Q2 2019 and held it in 26 quarters. The position peaked at $72.1M in Q3 2022. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Goldman Sachs reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Goldman Sachs sold 855,766 Akero Therapeutics shares in Q4 2025, an estimated $40.6M.
Goldman Sachs first reported a position in Akero Therapeutics in Q2 2019 and held it in 26 quarters.
Goldman Sachs's Akero Therapeutics position peaked at $72.1M in Q3 2022.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Goldman Sachs's 13F filing for Q4 2025, filed 10 Feb 2026.